<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37310438</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1621</StartPage><EndPage>1627</EndPage><MedlinePgn>1621-1627</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05347-w</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To characterize the antibody response to COVID-19 mRNA vaccination in patients with Systemic Lupus Erythematosus (SLE) and identify predictors of poor response.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">SLE patients who are followed at the Beth Israel Deaconess Medical Center Lupus Cohort (BID-LC) were enrolled. SARS-CoV-2 IgG Spike antibody was measured in patients who received two doses of either the BNT162b2 (Pfizer-BioNTech) or the mRNA-1273 (Moderna) COVID-19 vaccine (n&#x2009;=&#x2009;62). We defined non-responders as patients with an IgG Spike antibody titer less than two-fold (&lt;&#x2009;2) the index value of the test and responders as patients with antibody levels greater or equal to two-fold (&#x2265;&#x2009;2). A web-based survey was used to collect information regarding immunosuppressive medication use and SLE flares after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In our cohort of lupus patients, 76% were vaccine responders. The use of two or more immunosuppressive drugs was associated with being a non-responder (Odds Ratio 5.26; 95% CI 1.23-22.34, p&#x2009;=&#x2009;0.02). Both Belimumab use and higher Prednisone dose were associated with vaccine non-response (p&#x2009;=&#x2009;0.04 and p&#x2009;=&#x2009;0.04). The non-responder group had higher mean levels of serum IL-18 than the responder group (p&#x2009;=&#x2009;0.04) as well as lower C3 levels (p&#x2009;=&#x2009;0.01). Lupus flares and breakthrough infections were uncommon post-vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunosuppressive medications have a negative impact on vaccine humoral response in SLE individuals. We observed a trend towards vaccine no-response in BNT162b2 recipients and a relationship between IL-18 and impaired antibody response that merits further investigation.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Parsons</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2856-6308</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, MA, CLS-93602215, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rubio</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6320-2086</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, MA, CLS-93602215, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulougoura</LastName><ForeName>Afroditi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0161-3322</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, MA, CLS-93602215, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishfield</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, MA, CLS-93602215, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyttaris</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7652-3826</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, MA, CLS-93602215, Boston, USA. vkyttari@bidmc.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. vkyttari@bidmc.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711953">mRNA Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020382" MajorTopicYN="N">Interleukin-18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID mRNA vaccination</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Predictors</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37310438</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05347-w</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05347-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384:403&#x2013;416. https://doi.org/10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603&#x2013;2615. https://doi.org/10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D (2022) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330&#x2013;1338. https://doi.org/10.1136/annrheumdis-2021-220647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R, Grimshaw AA, Konig MF et al (2022) SARS-CoV-2 Infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol 74:766&#x2013;775. https://doi.org/10.1002/art.42030</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42030</ArticleId><ArticleId IdType="pubmed">34807517</ArticleId><ArticleId IdType="pmc">9011807</ArticleId></ArticleIdList></Reference><Reference><Citation>Papagoras C, Fragoulis GE, Zioga N (2022) Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis 81:1013&#x2013;1016. https://doi.org/10.1136/annrheumdis-2021-221539</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221539</ArticleId><ArticleId IdType="pubmed">34758975</ArticleId></ArticleIdList></Reference><Reference><Citation>Madelon N, Lauper K, Breville G et al (2022) Robust T-cell responses in anti-CD20-treated patients following covid-19 vaccination: a prospective cohort study. Clin Infect Dis 75:e1037&#x2013;e1045. https://doi.org/10.1093/cid/ciab954</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab954</ArticleId><ArticleId IdType="pubmed">34791081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R, Kristensen S, Dalgaard LPH (2021) Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from denmark. J Clin Med 10:3842. https://doi.org/10.3390/jcm10173842</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173842</ArticleId><ArticleId IdType="pubmed">34501290</ArticleId><ArticleId IdType="pmc">8432052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoglio IM, Valim JML, Daffre D (2021) Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study Of 252 119 patients. ACR Open Rheumatol 3:804&#x2013;811. https://doi.org/10.1002/acr2.11329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11329</ArticleId><ArticleId IdType="pubmed">34423922</ArticleId><ArticleId IdType="pmc">8593786</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Gartshteyn Y, Ricker E (2021) The Use of COVID-19 vaccines in patients with SLE. Curr Rheumatol Rep 23:79. https://doi.org/10.1007/s11926-021-01046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01046-2</ArticleId><ArticleId IdType="pubmed">34767100</ArticleId><ArticleId IdType="pmc">8586600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Liew JW, Kennedy K et al (2021) Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey. RMD Open 7:e001814. https://doi.org/10.1136/rmdopen-2021-001814</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001814</ArticleId><ArticleId IdType="pubmed">34493645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki EFN, Borba EF, Pasoto SG (2022) Impact of distinct therapies on antibody response to sars-cov-2 vaccine in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 74:562&#x2013;571. https://doi.org/10.1002/acr.24824</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24824</ArticleId><ArticleId IdType="pubmed">34806342</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB (2022) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375:43&#x2013;50. https://doi.org/10.1126/science.abm3425</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288&#x2013;291. https://doi.org/10.1093/rheumatology/kes146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes146</ArticleId><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Goldsmith CH, Urowitz MB (2000) The systemic lupus international collaborating clinics/american college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373&#x2013;376</Citation><ArticleIdList><ArticleId IdType="pubmed">10685799</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 IgG Assays. Siemens Healthineers. https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov-2-igg-assay . Accessed 5 Feb 2023</Citation></Reference><Reference><Citation>Freeman J, Conklin J (2021) Standardization of two SARS-CoV-2 serology assays to the WHO 20/136 human standard reference material. J Virol Methods 300:114430. https://doi.org/10.1016/j.jviromet.2021.114430</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114430</ArticleId><ArticleId IdType="pubmed">34915088</ArticleId><ArticleId IdType="pmc">8667347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammitzb&#xf8;ll C, Bartels LE, B&#xf8;gh Andersen J (2019) Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 3:622&#x2013;628. https://doi.org/10.1002/acr2.11299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11299</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Kim MY, Samanovic M (2022) Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol 74:284&#x2013;294. https://doi.org/10.1002/art.41937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gils MJ, Lavell A, van der Straten K (2022) Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 19:1003991. https://doi.org/10.1371/journal.pmed.1003991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003991</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam N, Sheils NE, Jarvis MS, Cohen K (2022) Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun 13:2377. https://doi.org/10.1038/s41467-022-30059-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30059-3</ArticleId><ArticleId IdType="pubmed">35501319</ArticleId><ArticleId IdType="pmc">9061778</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L (2021) Comparison of SARS-CoV-2 antibody response following vaccination With BNT162b2 and mRNA-1273. JAMA 326:1533&#x2013;1535. https://doi.org/10.1001/jama.2021.15125</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15125</ArticleId><ArticleId IdType="pubmed">34459863</ArticleId><ArticleId IdType="pmc">8406205</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Joyce D, Haag K (2023) Effect of systemic lupus erythematosus and immunosuppressive agents on covid-19 vaccination antibody response. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.25094</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.25094</ArticleId><ArticleId IdType="pubmed">36861682</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cirera S, Calvet J, Berenguer-Llergo A (2022) Glucocorticoids&#x2019; treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci Rep 12:14772. https://doi.org/10.1038/s41598-022-18996-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18996-x</ArticleId><ArticleId IdType="pubmed">36042275</ArticleId><ArticleId IdType="pmc">9427088</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M (2022) BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis 81:575&#x2013;583. https://doi.org/10.1136/annrheumdis-2021-221097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M, Feng Y, Wang Y (2021) Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis. Sci Rep 11(1):4707. https://doi.org/10.1038/s41598-021-84170-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84170-4</ArticleId><ArticleId IdType="pubmed">33633218</ArticleId><ArticleId IdType="pmc">7907126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>